Skip to content

Discipline: Nucleaire Geneeskunde

Nieuwe PET/CT-scanner: patiënten sneller en dichter bij huis bediend

Nieuwe PET/CT-scanner: patiënten sneller en dichter bij huis bediend

Op 11 juli 2017 is op campus Sint-Jan de nieuwe PET/CT-scanner in gebruik genomen. Een wereldprimeur, want het gaat om een PET/CT-scanner van de nieuwste generatie die als eerste in zijn soort geïnstalleerd werd. Deze waardevolle aanwinst in de diagnostische beeldvormingsmogelijkheden op de dienst Nucleaire Geneeskunde brengt dit onderzoek voor heel wat patiënten dichter bij huis.

‘The Radium Water Worked Fine until His Jaw Came Off’… of hoe gif nuttig kan zijn voor botgemetastaseerd prostaatcarcinoom

‘The Radium Water Worked Fine until His Jaw Came Off’… of hoe gif nuttig kan zijn voor botgemetastaseerd prostaatcarcinoom

Sinds de ontdekking van het eerste radiumisotoop aan het einde van de 19de eeuw legde de kennis over dit chemische element…

Het oncologisch centrum breidt uit

Het oncologisch centrum breidt uit

Stijgend aantal kankerpatiënten en nood aan verhoogd patiëntencomfort worden opgevangen door bouw nieuwe vleugel

PET/CT: het beste uit twee werelden

PET/CT: het beste uit twee werelden

In maart 2004 werd in Kortrijk het PET Centrum West-Vlaanderen opgericht. Dit is een samenwerking tussen drie ziekenhuizen (AZ Sint-Jan AV Brugge, Heilig Hart Ziekenhuis Roeselare en AZ Groeninge Kortrijk), die samen het eerste PET/CT toestel van West-Vlaanderen in gebruik namen.



Non-Hodgkin lymfoom, waarvan de incidentie wereldwijd toeneemt, is een frequente diagnose, met een incidentie van ongeveer 10 gevallen per 100.000 mannen en 8 gevallen per 100.000 vrouwen. Onder de noemer non-Hodgkin lymfoom worden een groot aantal aandoeningen gegroepeerd met een sterk uiteenlopend klinisch gedrag. De globale groep wordt dan ook vaak opgedeeld in laaggradige lymfomen, die traag maar gestadig evolueren en hooggradige lymfomen, die veeleer agressief evolueren.


Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management

High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept.

PMID: 34442033 PMCID: PMC8397229 DOI: 10.3390/jcm10163737

[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.

PMID: 36253663 PMCID: PMC10172288 DOI: 10.1007/s11307-022-01776-4

18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.

PMID: 35690515 DOI: 10.1016/j.eururo.2022.05.010

Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.

PMID: 35411446 DOI: 10.1007/s11307-022-01724-2

Bone scan findings in calcific tendinitis at the gluteus maximus insertion: some illustrative cases.

Radiol Case Rep; accepted for publication

Aspecific uptake of 68Ga-PSMA in Paget disease of the bone.

Clin Nucl Med 2016;41:877-878.

Incidental finding of silent appendicitis on 18F-FDG PET/CT in a patient with lung adenocarcinoma.

Hell J Nucl Med 2016;19:164-166.

18F-FDG PET imaging in granulomatosis with polyangiitis.

Hell J Nucl Med 2016;19:5-6.

18F-FDG PET imaging of granulomatosis with polyangiitis – Wegener’s Syndrome.

Hell J Nucl Med 2016;19:53-56.

When beauty hides a beast.

JBR-BTR 2014;97:192-193.

Camelid reporter gene imaging: a generic method for in vivo cell tracking.

EJNMMI Res 2014;4:32.

Positron Emission Tomography in Head and Neck Cancer.

Head and Neck Cancer Imaging, 2006; 17: 329-344, R. Hermans (Ed.), Springer.

Thyroid cancer: 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography.

Cancer Imaging (Volume 2), 2007; 3.55:699-706, M.A. Hayat (Ed.), Elsevier Academic Press. ISBN978-3-540-22027-5

Sternal foramen simulating osteolytic lesion on scintigraphy and SPET Imaging.

Ann Nucl Med Sci. 2002; 15:227-230

Hypertrophic osteitis of the clavicle.

Clin Nucl Med. 2003; 28(12): 990-1.

Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.

Eur J Nucl Med Mol Imaging. 2003; 30(12): 1615-9.

FDG-accumulation in inguinal herniation mimicking metastatic disease.

Clin Nucl Med. 2004; 29(10): 652-3

18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer.

Curr Opin Oncol. 2005; 17(3):249-53.

18FDG PET in oncology: the best and the worst (Review).

Int J Oncol. 2006; 28(5):1249-61.

Thyroid cancers.

Rev Med Brux. 2009 Sep;30(4):279-86.

Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue.

BMJ Case Reports 2010; doi:10.1136/bcr.02.2010.2750

The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer.

Radiother Oncol. 2010 Aug;96(2):145-52.

Non Hodgkin’s lymphomas: a major breakthrough with immunotherapy.

2011/03 - 2011/04
Rev Med Brux. 2011 Mar-Apr;32(2):83-92

Radioembolization of the Spleen: A Revisited Approach for the Treatment of Malignant Lymphomatous Splenomegaly.

Cardiovasc Intervent Radiol. 2012 Sep 25.

Port-site metastasis after explorative laparoscopy for an incidental appendiceal mucinous cystadenocarcinoma detected with FDG PET/CT.

JBR-BTR. 2013 Jan-Feb;96(1):43.

Nuclear imaging in relapsing polychondritis.

J Clin Rheumatol 2013;19:55-56.

Improved quantification in pinhole gated myocardial perfusion SPECT using micro-CT and ultrasound information.

Contrast Media Mol Imaging 2012;7:167-174.

Cortisone associated diverticular perforation.

JBR-BTR 2011;9:348-349.

Unilateral breast uptake of 99mTc-pertechnetate.

Hell J Nucl Med 2011;14:76-77.

Multimodality imaging of cardiac involvement in neurofibromatosis.

J Am Coll Cardiol 2011;57:e209.

18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis.

Eur J Nucl Med Mol Imaging 2011;38:1390-1391.

Rapid hepatic clearance of 99mTc-TMEOP: a new candidate for myocardial perfusion imaging.

Contrast Media Mol Imaging 2011;6:178-188.

Utility of pelvic bone SPET in imaging urinary bladder filling defects in urinary bladder carcinoma, compared with axial CT findings.

Hell J Nucl Med 2010;13:59-62.

Regional quantitative analysis of small animal myocardial sympathetic innervation and initial application in streptozotocin induced diabetes.

Contrast Media Mol Imaging 2009;4:174-182.

Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.

Clin Chem 2009;55:1434-1433.


“ The Invisible doctor”.

‘PSMA: de vlag en de lading’.


Minimal count level required for quantification of left ventricular function with gated myocardial perfusion tomography.


Comparison of 180-degree and 360-degree data acquisition in gated myocardial perfusion and in gated blood pool tomography.


Non-invasive measurement of left ventricular function in rats using pinhole gated myocardial perfusion tomography.


Reproducibility of left ventricular function measurements in rat using pinhole gated blood pool tomography.


Dose of 18FDG required for whole body PET using an LSO-PET camera.


Lung scintigraphy for the detection of pulmonary embolism: Evolution and current status in Belgium.


Apport de la tomoscintigraphie osseuse du thorax dans le bilan pré-thérapeutique (TEP-FDG inclus) des tumeurs pulmonaires.


Left ventricular function measured by QGS algorithm from 18FDG gated PET heart studies.


Potential pitfall due to IV-administration of FDG via a port-a-cath.


Comparison of 2- and 3-dimensional clinical FDG-PET studies.


FDG PET predicts prognosis of patients with resectable metastatic colorectal cancer (CRC) treated with preoperative chemotherapy.


68Ga-DOTATOC PET/CT in recurrent medullary thyroid carcinoma.


Safety and efficacy of radioimmunotherapy with 90Y-rituximab in patients with relapsed or refractory CD 20+ B cell non Hodgkin’s lymphoma: a pilot study.


Immuno-PET/CT imaging with 89Zr-Rituximab as a prelude for radioimmunotherapy with 90Y-Rituximab in patients with relapsed CD20+ B-Cell non-Hodgkin’s lymphoma.


Role of FDG-PET/CT in Hodgkin’s lymphomas: clinical assessment in a single center.


Zirconium-89 quantification with PET-CT Discovery LS.


Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+ B-Cell non-Hodgkin’s lymphoma: comparison with 18FDG-PET/CT.


SPECT-CT and the Sentinel Lymph Nodes in Breast cancer patients: additional diagnostic value of CT analysis.


The role of FDG PET(CT) for diagnosis of peritoneal carcinomatosis of colorectal origin.


Comparison of two 68Gallium-labeled octreotide analogues for molecular PET(CT) imaging of neuroendocrine tumours.


Bone marrow activity on 89Zr-rituximab immunoPET/CT predicts hematological toxicity in lymphoma patients treated with 90Y-rituximab.


Contribution of the end-diastolic images in gated perfusion SPECT for the diagnosis of coronary artery disease in women.


180- or 360-degree data acquisition for gated perfusion and blood pool SPECT.


Pinhole gated myocardial SPECT in rats: in-vivo measurement of pharmacologically induced cardiodepressive and cardiostimulating effects.


Measurement of the cardio-depressive effects of volatile halogenated anesthetics in rats using pinhole gated myocardial perfusion SPECT.


Reproducibility of left ventricular function measurements in rat using pinhole gated blood pool tomography.


Retrospective evaluation of the clinical value of planar bone scan and SPECT in primary staging (FDG-PET included) of pulmonary tumours.


Current and future strategies for optimising patient management through use of PET CT: PET CT in the management of lymphoma.


Can we predict the ablation of thyroid tissues after 131-iodine treatment for differentiated thyroid carcinomas (DTC)?


Clinical applications of SPECT/CT: from imagine to imaging.


8. K. Muylle

Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma: comparison with 18FDG-PET/CT.


7. K. Muylle, D. J. Vugts, N. Meuleman, G. Ghanem, P. Bourgeois, B. Vanderlinden, G. A. M. S. Van Dongen,…

Immuno-PET imaging with 89Zr-rituximab in patients with CD20+ B-cell lymphoma.


Apport de l’immuno-PET/CT dans les lymphomes CD20+.


Immuno-imaging in lymphoma.


New therapeutical use of nuclear medicine : RIT.


3D-dosimetry with 89Zr-immuno-PET/CT as a prelude to radio-immunotherapy: towards patient tailored image-guided therapy?


The role of molecular imaging in early drug development.

Back To Top